A Randomized, Open, Single-Dose, Single-Centre, Cross-Over, Phase I Study in Type 1 Diabetes Mellitus Patients to Estimate the Extent and Rate of Absorption of AZD1656 After Administration of a Tablet Formulation in the Fasting State and Just Before Food in Comparison With an Oral Suspension of AZD1656.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 04 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 08 Jan 2009 New trial record.